As inhibition of Mnks can block the synthesis of these pro-survival proteins and sensitize apoptosis in cancer cells, along with the non-essential role of Mnks in normal development [13], Mnk inhibitors could provide an effective but less toxic therapeutic strategy to brake the Ara-C resistance in AML therapy. The gene discussed is ATP7A; the disease is acute myeloid leukemia.